Completed PHASE3 INTERVENTIONAL 1-arm NCT00113568

Safety Study of XP12B in Women With Menorrhagia

Multicenter Study to Evaluate the Safety of XP12B in Women With Heavy Menstrual Bleeding Associated With Menorrhagia

Sponsor: Ferring Pharmaceuticals

Conditions Heavy Menstrual Bleeding Menorrhagia

Interventions Tranexamic acid tablets (XP12B)

Updated 8 times since 2017 Last updated: Jun 9, 2010 Started: Jun 30, 2005 Primary completion: May 31, 2009 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Heavy Menstrual Bleeding and Menorrhagia and is currently completed. Ferring Pharmaceuticals leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferring Pharmaceuticals

Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Alpharetta, United States , Billings, United States , Birmingham, United States , Boise, United States , Champaign, United States , Charlotte, United States , Chaska, United States , Cincinnati, United States , Colorado Springs, United States and 40 more locations